Biogen (LTS:0R1B) Short-Term Debt : $1,748 Mil (As of Sep. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Biogen Short-Term Debt?

Biogen's Short-Term Debt for the quarter that ended in Sep. 2024 was $1,748 Mil.

Biogen's quarterly Short-Term Debt declined from Mar. 2024 ($250 Mil) to Jun. 2024 ($0 Mil) but then increased from Jun. 2024 ($0 Mil) to Sep. 2024 ($1,748 Mil).

Biogen's annual Short-Term Debt declined from Dec. 2021 ($999 Mil) to Dec. 2022 ($0 Mil) but then increased from Dec. 2022 ($0 Mil) to Dec. 2023 ($150 Mil).

Biogen Short-Term Debt Historical Data

The historical data trend for Biogen's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Short-Term Debt Chart

Biogen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Debt

Get a 7-Day Free Trial

1,495.80

999.10

150.00

Biogen Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Short-Term Debt	Get a 7-Day Free Trial															500.00	150.00	250.00	-	1,748.10

Biogen Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Biogen Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Biogen's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Biogen Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (LTS:0R1B) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

BIIB:USA BIIB:Mexico 1BIIB:Italy IDP:Germany IDP:Germany IDP:Germany IDP:Germany BIIB34:Brazil BIIB:Austria BIIB:Argentina

Address

225 Binney Street, Cambridge, MA, USA, 02142

Website

https://www.biogen.com

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.

Biogen Headlines

No Headlines